![TLR signaling in bone marrow DCs contributes to TLR1/2 agonist–induced HSPC expansion. (A) Bone marrow from Zbtb46-Cre, Myd88f/f, or Myd88f/f mice were transplanted into irradiated wild-type recipient mice; 8 weeks later, mice were treated with PAM3CSK4 (100 μg, every other day × 3 doses) and analyzed 24 hours after the final dose. (B) Expression of Myd88 mRNA relative to β-actin mRNA from sorted bone marrow DCs, monocytes, and macrophages. Number of LSK (C) or LSK-SLAM (D) cells per femur. (E) Number of LSK Flk2– CD48+ CD150+ cells (multipotent progenitor-2 [MPP2]), LSK Flk2– CD48+ CD150– cells (MPP3), and LSK Flk2+ cells (MPP4) in the bone marrow. (F) Number of common myeloid progenitors (CMPs), GMPs, and megakaryocyte-erythroid progenitors (MEPs) in bone marrow. (G) Number of colony-forming unit cells (CFU-C) per spleen. (H) Number of LSK cells per spleen. Data represent the mean ± standard error of the mean. Statistical significance determined by using a one-way analysis of variance. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/140/14/10.1182_blood.2022016084/4/blood_bld-2022-016084-gr5.jpeg?Expires=1722696667&Signature=Q5upZU~RwkpmZGcGPQ8UED-dmAi4W-ymC84qJoDW53O48K8x09qikrsR4lBqAg~grwjyvyu~0Jfr2-4RD2qOg5Owrr3NZrY7QDTn7kVT1txhOjQRSKpBOfTTFOyjLwIWaQ7gd4kyaniX-9RUI-SJeMrdWyiQBao-0B66ZeSEEmEuiB2p~kA6J8gBeKpMZTeFyX~szV~42H0oqQUGXeF7H5~S6HLsszfgNKqebuJwLEUsHdoAD0G94gHvMNI-B5oxkPU1uLb0ucOzU1vs3umtisb7xqN6tYp0EMGWcV2eJfFnYIUoZe16fhGHmKVwlHyHCJBmzKxS08yWgpNnitSwiw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TLR signaling in bone marrow DCs contributes to TLR1/2 agonist–induced HSPC expansion. (A) Bone marrow from Zbtb46-Cre, Myd88f/f, or Myd88f/f mice were transplanted into irradiated wild-type recipient mice; 8 weeks later, mice were treated with PAM3CSK4 (100 μg, every other day × 3 doses) and analyzed 24 hours after the final dose. (B) Expression of Myd88 mRNA relative to β-actin mRNA from sorted bone marrow DCs, monocytes, and macrophages. Number of LSK (C) or LSK-SLAM (D) cells per femur. (E) Number of LSK Flk2– CD48+ CD150+ cells (multipotent progenitor-2 [MPP2]), LSK Flk2– CD48+ CD150– cells (MPP3), and LSK Flk2+ cells (MPP4) in the bone marrow. (F) Number of common myeloid progenitors (CMPs), GMPs, and megakaryocyte-erythroid progenitors (MEPs) in bone marrow. (G) Number of colony-forming unit cells (CFU-C) per spleen. (H) Number of LSK cells per spleen. Data represent the mean ± standard error of the mean. Statistical significance determined by using a one-way analysis of variance. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.
